Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Liver function and drug processing: a new study

NCT ID NCT06916078

First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 26 times

Summary

This study looks at how lepodisiran enters the blood and leaves the body in people with mild, moderate, or severe liver issues compared to those with healthy livers. About 33 adults will receive a single injection under the skin and be monitored for up to 9 weeks. The goal is to understand safety and how the liver affects the drug's levels.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • American Research Corporation at Texas Liver Institute

    RECRUITING

    San Antonio, Texas, 78215, United States

    Contact Phone: •••-•••-••••

    Contact

  • CRU Early Phase Unit

    RECRUITING

    Kistarcsa, H-2143, Hungary

    Contact Phone: •••-•••-••••

    Contact

  • Clinical Pharmacology of Miami

    RECRUITING

    Miami, Florida, 33014-3616, United States

    Contact Phone: •••-•••-••••

    Contact

  • Orlando Clinical Research Center

    RECRUITING

    Orlando, Florida, 32809, United States

    Contact Phone: •••-•••-••••

    Contact

Conditions

Explore the condition pages connected to this study.